Delivery Order SPE2DB24D1007-SPE2DB24FBZDL

Award Date 4/18/24
Potential Completion Date 4/19/24
Potential Value $18K
Ultimate Awardee
Cencora, Inc.
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award is for the delivery of REXULTI 1 MG TABLET 30S, a pharmaceutical product, to the Defense Logistics Agency (DLA). The contract was awarded to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., a major pharmaceutical distributor. The contract is a Delivery Order with a Firm Fixed Price type and has a ceiling value of $14,605.44 with a completion date of January 12, 2024. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the...
This federal contract award is for the delivery of REXULTI 1 MG Tablets in quantities of 30's, awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The $7,192.98 Delivery Order contract has a firm fixed price, with a period of performance through July 1, 2024. The contracting agency is the Defense Logistics Agency (DLA), a defense agency of the U.S. Department of Defense. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This federal contract award is for the delivery of REXULTI 1 MG TABLET 30S, a pharmaceutical product, to the Defense Logistics Agency (DLA). The prime contractor is Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order with a Firm Fixed Price of $1,831.84 and a completion date of December 20, 2024. This award is not associated with any set-aside designation, indicating open competition. Amerisourcebergen Drug Corp...
This federal contract award is for the delivery of REXULTI 1 MG TABLET 30S, a pharmaceutical product, to the Defense Logistics Agency (DLA). The $9,179.99 fixed-price delivery order was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has an ultimate completion date of November 13, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical division, which serves as...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $14,998.80 firm-fixed-price delivery order is for the supply of REXULTI 1 MG TABLET 30S, a pharmaceutical product. The award is part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as...
This federal contract award is for the delivery of REXULTI 2 MG TABLET 30S, a pharmaceutical product, to the Defense Logistics Agency (DLA). The contract has a ceiling value of $7,056.20 and was awarded to the prime contractor, Amerisourcebergen Drug Corp, on May 21, 2024. The contract is a Firm Fixed Price Delivery Order and does not have a set-aside designation. Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, is a major supplier of pharmaceutical products and...
This federal contract award is for the delivery of REXULTI 0.5 MG TABLET 30S, a pharmaceutical product, to the Defense Logistics Agency (DLA). The contract has a ceiling value of $3,255.24 and was awarded to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., as the prime contractor. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) between Cencora, Inc. and the DLA, valued at up to $999,999,999.00 and running through November 2026. This IDC serves as the...
This federal contract award is for the delivery of REXULTI 0.5 MG TABLET 30S pharmaceutical products to the Defense Logistics Agency (DLA). The $6,034.90 firm-fixed-price delivery order was issued to the prime contractor, Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract has an ultimate completion date of May 11, 2023 and was awarded on May 10, 2023. This contract is not set aside for any specific business type. Amerisourcebergen Drug Corp is a major pharmaceutical...
The U.S. Defense Logistics Agency (DLA) awarded Amerisourcebergen Drug Corporation, a subsidiary of Amerisourcebergen Corporation, a firm fixed price delivery order contract valued at $6,296.68 for the supply of REXULTI 0.5 MG TABLET 30S. This delivery order is part of a larger indefinite delivery contract (IDC) awarded solely to Amerisourcebergen Drug Corp by DLA, with a potential value of $999,999,999.00 and a performance period through December 31, 2025. The IDC serves as the primary contract...
This federal contract award is for the delivery of Rexulti 1 mg tablets to the Defense Logistics Agency (DLA). The $4,552.35 delivery order was issued under an Indefinite Delivery Contract (IDC) held by Amerisourcebergen Drug Corp, a major pharmaceutical distributor, with the DLA Troop Support Medical. The IDC, valued at up to $999,999,999, serves as the primary vehicle for Amerisourcebergen to provide a comprehensive range of pharmaceutical products and medical supplies to support military...
  • SPE2DB24D1007
    Indefinite Delivery Contract
  • SPE2DB24D1007-SPE2DB24FBZDL
    Delivery Order

This federal contract award is for the delivery of REXULTI 1 MG TABLET 30S pharmaceutical products to the Defense Logistics Agency (DLA), a defense agency. The contract was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for an estimated ceiling value of $17,516.16. The award represents a delivery order under Amerisourcebergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued up to $999,999,999.00 through December 2025. This single-award IDC serves as Amerisourcebergen's primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to DLA facilities supporting the Department of Defense worldwide. The contract does not have a set-aside designation. Amerisourcebergen Drug Corp is a subsidiary of the larger Cencora, Inc. parent company.

Generated 7/18/24, 9:04 AM